The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]
Data from the phase 2 open label extension study investigating subcutaneous injections of nomlabofusp for Friedreich ataxia is expected in the fourth quarter of 2024.
Phase 2 biomarker trial participants who completed 156 weeks of treatment were offered enrollment into another 52-week extension to continue to observe safety, assessments of plasma biomarkers, and cognitive effects, among others.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Michael Rogawski, MD, PhD. [LISTEN TIME: 12 minutes]
The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]
In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain lesions.
The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.
The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester talked about recent results on the phase 3 ACCORD trial assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 8 minutes]
The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.
Lassell et al present a use case demonstrating the process of moving an unmet need to the “solution space” of the Innovation Biodesign Framework for addressing a healthcare challenge in a specific at-risk population: Alzheimer disease and AD-related dementias.
The original approval for chorea associated with Huntington disease was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point.
The FDA approval of Medtronic’s spinal cord stimulator makes it the first on the market to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time for chronic pain.
The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]
Neal K. Shah, CEO of CareYaya Health Technologies, discussed how emerging neurotechnology, such as mobile EEG devices paired with customized AI and machine learning models, is poised to transform the fight against dementia.
In comparison to previously approved treatments like satralizumab and inebilizumab, ravulizumab-treated patients performed significant better on outcomes of first relapse and time to first relapse.
Ravulizumab reduced NfL levels in cerebrospinal fluid and serum whereas eculizumab showed no change in NfL when compared with placebo.
The professor of neurology and pharmacology at the University of California Davis Health Medical Center gave commentary on the FDA approval of Aquestive Therapeutics’ buccal film in pediatric patients with intermittent, stereotypic episodes of frequent seizure activity.
The professor of neurology at Mayo Clinic talked about MOG-antibody associated disease, a relatively newly recognized demyelinating condition of the central nervous system. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on primary progressive aphasia.
As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Kelly Papesh, DNP, APRN, FNP-BC, executive director of the Association of Movement Disorder Advanced Practice Providers.
In recent news, Lexeo Therapeutics' gene therapy candidate LX2006 received FDA fast track designation for patients with Friedreich ataxia cardiomyopathy.
Neurology News Network. for the week ending April 27, 2024. [WATCH TIME: 3 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 26, 2024.
The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]
Stephen Samples, MD, chair of Allegheny Health Network’s department of neurology, gave commentary towards the AHS’s recent statement paper addressing CGRP-targeting therapies as a first-line option for preventive migraine.
The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]
Satralizumab, an IL-6 receptor inhibitor, shows promise in reducing infection rates compared to historical data.
In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.
A recent study showed the relationship between genes associated with lysosomal function and environmental exposure to pesticides in Parkinson disease.
